<DOC>
	<DOCNO>NCT02944383</DOCNO>
	<brief_summary>A 12-Week , Phase 2 Randomized , Double-Blind , Placebo-Controlled Study Assess Efficacy Safety Tolerability Gemcabene Subjects Severe Hypertriglyceridemia ( INDIGO-1 )</brief_summary>
	<brief_title>A 12-Week Study Assess Efficacy Safety Tolerability Gemcabene Subjects With Severe Hypertriglyceridemia</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<criteria>Subjects meet follow criterion eligible participate study : 1 . Provision write sign inform consent ( subject legal guardian ) prior studyspecific procedure ; 2 . Male female ( neither pregnant lactating ) ≥18 year age time consent ; 1 . Women childbearing potential must negative serum pregnancy test Screening Visit negative urine dipstick Study Day 1 prior dose order qualify study . Women surgically sterile clinically confirm postmenopausal ( i.e. , document amenorrhea ≥ 1 year absence biological physiological cause ) consider childbearing potential ; 2 . Women childbearing potential must agree use acceptable method contraception throughout duration study 30 day last dose study drug . For study , doublebarrier contraception require . 3 . Currently selfreported , stable , lowfat , lowcholesterol diet combination stable statin without ezetimibe ( 10 mg QD ) least 12 week prior Screening Visit ; 4 . Mean fast TG value ≥ 500 mg/dL &lt; 1500 mg/dL ( high value 50 % great low value ) S1 S2 Visits ( alternatively S2 S3 ) ; 5 . Physical examination , include vital sign , within normal limit clinically acceptable Investigator ; 6 . Weight ≥ 50 kg ; body mass index ( BMI ) ≤ 45 kg/m² ; 7 . Subjects Type 2 diabetes take antidiabetes pharmacologic therapy must stable regimen least 3 month , plan change medication study duration . Subjects meet follow criterion exclude participation study : 1 . Known previously document homozygous genetic deficiency ( LPL , ApoCII , ApoCIII , ApoAV , GPIHBP1 , LMF1 ) ; 2 . History pancreatitis within last 6 month prior screen ( Visit S1 ) ; 3 . History bariatric surgery ; symptomatic gallstone disease , unless treat cholecystectomy ; 4 . Abnormal liver function test PreScreening Visit Screening Visits ( aspartate aminotransferase alanine aminotransferase &gt; 2 × upper limit normal [ ULN ] , total bilirubin &gt; 1.5 × ULN , alkaline phosphatase &gt; 2 × ULN base appropriate age gender normal value ) . Subjects bilirubin &gt; 1.5 × ULN history Gilbert 's syndrome may include ; reflexive direct bilirubin test use confirm Gilbert 's syndrome ; 5 . Active liver disease ( e.g. , cirrhosis , alcoholic liver disease , hepatitis B [ HBV ] , hepatitis C [ HCV ] , autoimmune hepatitis , liver failure , liver cancer ) , history liver transplant , know diagnosis human immunodeficiency virus ( HIV ) , acquire immune deficiency virus ; 6 . Moderate severe renal insufficiency define estimate GFR &lt; 60 mL/min/1.73 m2 ( calculate use The Chronic Kidney Disease Epidemiology Collaboration equation ) PreScreening Visit Screening Visits ; 7 . Abnormal urinalysis ( proteinuria great trace male nonmenstruating female great trace hematuria ) , confirm reflexive urine protein : creatinine ratio test ; 8 . Uncontrolled thyroid disease : hyperthyroidism hypothyroidism define thyroid stimulate hormone ( TSH ) low limit normal &gt; 1.5 × ULN , respectively , base result PreScreening Visit Screening Visit . If control , treatment stable least 3 month prior Screening Visit ; 9 . Type 1 diabetes mellitus uncontrolled type 2 diabetes mellitus HbA1c value ≥8.5 % base result PreScreening Visit Screening Visit ) , diabetic subject take thiazolidinedione ( e.g. , pioglitazone , rosiglitazone ) ; 10 . New York Heart Association Class III IV heart failure ( see Appendix C ) ; 11 . Myocardial infarction , severe unstable angina pectoris , coronary angioplasty , coronary artery bypass graft , major cardiovascular event result hospitalization within 3 month Screening Visit ( S1 ) . Subjects adequately treat stable angina , per Investigator assessment , may include ; 12 . Uncontrolled cardiac arrhythmia prolong QT Screening Visit Study Day 1 prior dose ECG ( QTcF &gt; 450 msec men &gt; 470 msec woman ) know family history prolong QT unexplained sudden cardiac death ; 13 . Uncontrolled hypertension , define sit systolic blood pressure ≥ 180 mmHg diastolic blood pressure ≥ 110 mmHg , confirm repeat measurement ; 14 . Currently receive cancer treatment ( ) , Investigator 's opinion , risk relapse recent cancer ; 15 . Inadequate washout PCSK9 inhibitor ( 8 week prior Screening Visit S1 ) , fibrate lipid lower agent ( 6 week prior Screening Visit S1 ) , niacin &gt; 200 mg/day , OMG3 , bile acid sequestrants lipid lower therapy ( 4 week prior Screening Visit S1 ) ; 16 . Use excluded medication supplement within 3 month prior S1 ( e.g. , potent cytochrome P450 [ CYP ] 3A4 inhibitor , see Appendix D ) ; 17 . Hypersensitivity history significant adverse reaction fibrate lipid regulating agent ; 18 . History drug alcohol abuse within past year inability comply protocol requirement , include subject alcohol restriction ( see Section 5.6.3 ) ; 19 . Previously treat gemcabene ( i.e. , CI1027 ) ; participation another clinical study investigational agent device concurrently within 1 month prior Screening Visit , use investigational agent within 1 month 5 halflives ( know ) , whichever longer , prior Screening Visit ; 20 . Any finding , opinion Investigator , would compromise subject 's safety participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hypertriglycerides</keyword>
</DOC>